Lege Artis Medicinae

[THE ROLE OF ENZYME REPLACEMENT THERAPY IN PANCREATIC DISEASES ASSOCIATED WITH MALDIGESTION]

TAKÁCS Tamás

FEBRUARY 22, 2007

Lege Artis Medicinae - 2007;17(02)

[The pancreas synthesizes and secretes more than 20 digestive enzymes that hydrolyze the major nutritive components, i.e., carbohydrates, fat and protein, within the lumen of the small bowel. In several pancreatic diseases the secretory capacity of the pancreas gradually decreases and the release of pancreatic juice becomes blocked resulting in the characteristic symptoms of maldigestion. Pancreas-associated maldigestion is most often caused by chronic pancreatitis, which can be diagnosed primarily by imaging beside history and clinical symptoms. There is no decisive serological test. The goal of the treatment of pancreatic insufficiency is to reduce symptoms (bloating, abdominal pain, weight loss, and, most importantly, steatorrhea) and improve digestion. One way to do this is to replace pancreatic enzymes. The efficiency of the available enzyme preparations can be increased by the improvement of lipase activity.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[57th Annual Meeting of the American Association for the Study of Liver Diseases]

PÉTER Zoltán

Lege Artis Medicinae

[Is there a need for infectologists?]

SZALKA András

Lege Artis Medicinae

[Zoonoses in focus]

LAKOS András

Lege Artis Medicinae

[The Sides of the Coin]

dr. ZSUZSA Gábor

Lege Artis Medicinae

[A RARE, HISTOLOGICALLY COMPLEX LIVER TUMOUR]

HIDVÉGI Judit, BAJTAI Attila, VARGA Árpád

[INTRODUCTION - Among the primary malignant tumours of the liver, hepatoblastoma is extremely rare in adults in contrast to its frequency in children. Only 23 such cases have been published to date. Mixed tumour of the liver and carcinosarcoma of the liver are used as synonyms for adult hepatoblastoma. The tumours have both mesenchymal and epithelial components (hepatocellular or cholangiocellular carcinoma) with focal bone and/or cartilage formation. CASE REPORT - A 78-year-old woman was admitted to the surgery department with increasing anaemia and persistent abdominal pain. An emergency operation was performed. Her peritoneal cavity was filled with blood due to the rupture of a tumour that occupied the right lobe of the liver. The neoplasm could only be removed partially. Despite an intensive care, the patient's state could not be stabilized and she died a day after the operation. The histological diagnosis was carcinosarcoma of the liver with an AFP- and cytokeratin-positive epithelial component and a spindle cell component positive for vimentin. The osteogen sarcoma found in the tumour was strongly positive for the S-100 protein. DISCUSSION - The authors review the hypotheses for the formation of adult primary hepatoblastoma, a combined tumour, they describe their various types and the immunohistochemical tests that are used in their identification.]

All articles in the issue

Related contents

Lege Artis Medicinae

[AUTOIMMUNE PANCREATITIS - AN UNDERDIAGNOSED DISEASE?]

CZAKÓ László

[Autoimmune pancreatitis is a recently recognized type of chronic pancreatitis that is clearly distinct from alcoholic chronic pancreatitis. Its clinical symptoms include jaundice, abdominal pain, weight loss and diabetes mellitus. It may be associated with other autoimmune diseases. IgG levels are elevated and autoantibodies can be detected. Pancreatic imaging reveals a diffuse enlargement of the pancreas and irregular narrowing of the main pancreatic duct. The characteristic histological features are lymphoplasmacytic infiltration and fibrosis. Autoimmune pancreatitis responds dramatically to steroid therapy, in contrast to other types of chronic pancreatitis, which hardly respond to any of the various therapies. It is important to be aware of this disease because it may be mistaken for other forms of chronic pancreatitis or pancreatic cancer, which leads to pancreatic resection when steroid treatment would be sufficient. This review discusses the clinical, laboratory, histological and imaging findings that are seen in autoimmune pancreatitis with particular focus on diagnosis. With the improvement of the diagnostic work-up less unnecessary pancreatic resections are expected to happen in patients with autoimmune pancreatitis.]

Hungarian Radiology

[Examination of pancreatic exocrine function with secretin stimulated magnetic resonance cholangiopancreatography]

ENDES János, CZAKÓ László, TAKÁCS Tamás, BODA Krisztina, LONOVICS János

[INTRODUCTION - The aim of this study was to assess the feasibility and usefulness of SS-MRPD for evaluation of the pancreatic exocrine function. PATIENTS AND METHODS - SS-MRPD was performed in 20 patients with mild (n=8) or severe (n=12) chronic pancreatitis (according to the grade of exocrine pancreatic insufficiency indicated by the Lundh test) and in 10 volunteers without pancreatic disease. MRPD images were evaluated before and 10 min after the iv. administration of 0.5 IU/kg secretin. The changes in pancreatic tissue T2 signal intensity and duodenal filling after the injection of secretin were determined by means of SS-MRPD. The SSMRPD findings were then compared with those of the Lundh test. RESULTS - The basal pancreatic T2 signal intensity was significantly higher in the patients with a mild or a severe exocrine pancreatic insufficiency as compared with the controls (826.5±36.36 and 908±80.51 vs 659.2±41.67). The pancreatic T2 signal intensity exhibited a significant elevation after secretin administration both in the volunteers and in the patients with mild or severe chronic pancreatitis. This elevation was significantly lower in both the mild and the severe chronic pancreatitis patients than in the volunteers (66.85±15.77 and 24.45±5.85, respectively, vs. 200.0± 45.07). After the administration of secretin, the diameter of the duodenum was significantly increased in all three groups. This duodenal filling was significantly reduced in patients with a mild or a severe exocrine pancreatic insufficiency as compared with the volunteers (4.12±1.33 and 1.70±0.77 vs. 15.38± 1.73). There was no significant difference in pancreatic T2 signal intensity changes or in duodenal filling in patients with a mild or a severe exocrine pancreatic insufficiency. There were significant correlations between the pancreatic T2 signal intensity changes and the duodenal filling and the results of the Lundh test (r= -0.616 and -0.78). CONCLUSION - These results demonstrate that the administration of secretin increases the T2 signal intensity of the pancreatic tissue and the diameter of the duodenum to different extents in normal subjects and in patients with chronic pancreatitis. This suggests that SS-MRPD can provide information of value in the assessment of an exocrine pancreatic insufficiency.]

Lege Artis Medicinae

[THE DIFFERENTIATION OF CHRONIC PANCREATITIS FROM PANCREATIC CANCER]

CZAKÓ László

[The poor prognosis of pancreatic cancer is mainly due to late diagnosis. The differentiation between pancreatic cancer and chronic pancreatitis is difficult, because the two diseases cause similar clinical symptoms and morphological alterations. Furthermore, chronic pancreatitis is associated with an increased risk of malignant transformation, thus the two diseases may be present simultaneously. The recent developments in molecular genetic tests and in imaging techniques, such as multidetector computed tomography, magnetic resonance cholangio- pancreatography, endoscopic ultrasoundguided fine needle aspiration and positron emission tomography/computed tomography, have fundamentally transformed the differentiation of the two disorders. This paper provides a systematic review of the recent evidence-based results concerning the differentiation of pancreatic cancer and chronic pancreatitis.]

Lege Artis Medicinae

[DISEASES OF THE EXOCRINE PANCREAS AND DIABETES MELLITUS]

CZAKÓ László

[Exocrine and endocrine pancreas constitutes close anatomical and functional links accordingly, any disease affecting one of these sectors will inevitably affect the other. Acute and chronic pancreatitis, pancreatic surgery, cystic fibrosis and pancreatic cancer are those pancreatic conditions that might cause diabetes mellitus. The development of diabetes greatly influences the prognosis and quality of life of patients with exocrine pancreatic diseases. The lack of glucagon and the impaired absorption of nutrients may cause life-threatening complications, such as hypoglycaemia, and the micro- and macrovascular complications may impair the organ functions. Diabetes mellitus is an independent risk factor of mortality in those with exocrine pancreatic diseases. Pancreatic diabetes is a distinct metabolic and clinical form of diabetes, requires special treatment. Diet and pancreatic enzyme replacement therapy may be sufficient in the early stages. Oral antidiabetic drugs are not recommended. If the diet proves inadequate to reach the glycaemic goals, regular insulin treatment is demanded. There are special impairments of the exocrine function and the pancreatic morphology at diabetic patients that resemble to chronic pancreatitis. Atrophy of the exocrine tissue may caused by the lack of trophic insulin. Hyperglycaemia can activate the stellate cells that lead to pancreatic fibrosis. The microangiopathy and neuropathy, as well as the lack of islet hormone action - responsible for the exocrine pancreas regulation - will cause further damage on the pancreas glandular tissue. In the event of a proven impairment of the pancreatic exocrine function in diabetes mellitus, pancreatic enzyme replacement therapy is recommended. This may improve the nutritional condition and decrease the metabolic instability.]

Clinical Neuroscience

[Pompe’s disease - Part II - Treatment strategies and enzyme replacement]

ILLÉS Zsolt, VÁRDI Visy Katalin

[Pompe’s disease is an ultra-orphan disease caused by the deficiency of lysosomal alpha-glucosidase. At present, it is the only inherited muscle disorder, which can be treated by replacement of the enzyme. Three international randomized trials examined the clinical efficacy of enzyme replacement therapy (ERT) in infantile and late-onset diseases. ERT reduced the risk of death, respiratory support, invasive ventilation and improved cardiomyopathy. Respiration, muscle function and quality of life were improved in both infantile and late-onset diseases. These randomized and pilot trials also proved the safety of the treatment. At present it is not clear if antibodies induced by ERT result in decreased efficacy. In this review, we also discuss our experiences obtained by the treatment of three patients, and review the spectrum of supportive and experimental treatment strategies.]